

# Ting-Tsung Chang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4824463/publications.pdf>

Version: 2024-02-01

106  
papers

13,267  
citations

117625

34  
h-index

31849

101  
g-index

107  
all docs

107  
docs citations

107  
times ranked

5725  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical characteristics and outcomes of drug-induced liver injury in Taiwan: With emphasis on the impact of chronic hepatitis B infection. <i>Journal of the Chinese Medical Association</i> , 2022, 85, 286-294.	1.4	4
2	Urine DNA biomarkers for hepatocellular carcinoma screening. <i>British Journal of Cancer</i> , 2022, 126, 1432-1438.	6.4	15
3	Ledipasvir/Sofosbuvir for Patients Coinfected With Chronic Hepatitis C and Hepatitis B in Taiwan: Follow-up at 108 Weeks Posttreatment. <i>Clinical Infectious Diseases</i> , 2022, 75, 453-459.	5.8	5
4	Impact of HCV viremia on HBV biomarkers in patients coinfecting with HBV and HCV. <i>BMC Infectious Diseases</i> , 2022, 22, 351.	2.9	1
5	Effectiveness and safety of ledipasvir/sofosbuvir for genotype 2 chronic hepatitis C infection: Real-world experience from Taiwan. <i>Journal of the Formosan Medical Association</i> , 2021, 120, 983-990.	1.7	4
6	Real-world outcome of immune checkpoint inhibitors for advanced hepatocellular carcinoma with macrovascular tumor thrombosis. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1929-1937.	4.2	19
7	Clinical Implications of Serum Hepatitis B Virus Pregenomic RNA Kinetics in Chronic Hepatitis B Patients Receiving Antiviral Treatment and Those Achieving HBsAg Loss. <i>Microorganisms</i> , 2021, 9, 1146.	3.6	4
8	Antiviral kinetics of tenofovir alafenamide and tenofovir disoproxil fumarate over 24 weeks in women of childbearing potential with chronic HBV. <i>PLoS ONE</i> , 2021, 16, e0251552.	2.5	4
9	Recurrent HBV Integration Targets as Potential Drivers in Hepatocellular Carcinoma. <i>Cells</i> , 2021, 10, 1294.	4.1	11
10	Drug-induced liver injury associated with severe cutaneous adverse drug reactions: A nationwide study in Taiwan. <i>Liver International</i> , 2021, 41, 2671-2680.	3.9	9
11	Detection of CTNNB1 Hotspot Mutations in Cell-Free DNA from the Urine of Hepatocellular Carcinoma Patients. <i>Diagnostics</i> , 2021, 11, 1475.	2.6	3
12	Herbal and dietary supplement-induced liver injury in Taiwan: comparison with conventional drug-induced liver injury. <i>Hepatology International</i> , 2021, 15, 1456-1465.	4.2	10
13	Detection of Hepatitis B Virus "Host Junction Sequences in Urine of Infected Patients. <i>Hepatology Communications</i> , 2021, 5, 1649-1659.	4.3	11
14	Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines. <i>Hepatology International</i> , 2021, 15, 1421-1430.	4.2	15
15	Plasma proteome atlas for differentiating tumor stage and post-surgical prognosis of hepatocellular carcinoma and cholangiocarcinoma. <i>PLoS ONE</i> , 2020, 15, e0238251.	2.5	13
16	Impact of Immune Checkpoint Inhibitors with or without a Combination of Tyrosine Kinase Inhibitors on Organ-Specific Efficacy and Macrovascular Invasion in Advanced Hepatocellular Carcinoma. <i>Oncology Research and Treatment</i> , 2020, 43, 211-220.	1.2	20
17	Genotyping of immune-related loci associated with delayed HBeAg seroconversion in immune-active chronic hepatitis B patients. <i>Antiviral Research</i> , 2020, 176, 104719.	4.1	3
18	An Effective and Efficient Algorithm for Detecting Exact Deletion Breakpoints from Viral Next-Generation Sequencing Data. , 2020, , .		1

#	ARTICLE	IF	CITATIONS
19	Contrast-Induced Acute Kidney Injury Among Patients With Chronic Kidney Disease Undergoing Imaging Studies: A Meta-Analysis. <i>American Journal of Roentgenology</i> , 2019, 213, 728-735.	2.2	20
20	Insulin Resistance Associated Disorders Pivoting Long-Term Hepatitis B Surface Antigen Decline During Entecavir Therapy. <i>Journal of Clinical Medicine</i> , 2019, 8, 1892.	2.4	1
21	Plasma proteome plus site-specific N-glycoprofiling for hepatobiliary carcinomas. <i>Journal of Pathology: Clinical Research</i> , 2019, 5, 199-212.	3.0	16
22	Telbivudine on IgG-associated hypergammaglobulinemia and TGF- $\beta$ 1 hyperactivity in hepatitis B virus-related liver cirrhosis. <i>PLoS ONE</i> , 2019, 14, e0225482.	2.5	2
23	Combined Transarterial Embolization/Chemoembolization-Based Locoregional Treatment with Sorafenib Prolongs the Survival in Patients with Advanced Hepatocellular Carcinoma and Preserved Liver Function: A Propensity Score Matching Study. <i>Liver Cancer</i> , 2019, 8, 186-202.	7.7	16
24	Fully galactosyl-fucosyl-bisected IgG1 reduces anti-HBV efficacy and liver histological improvement. <i>Antiviral Research</i> , 2019, 163, 1-10.	4.1	7
25	Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected With HBV. <i>Gastroenterology</i> , 2018, 154, 989-997.	1.3	97
26	Viral dynamics of persistent hepatitis C virus infection in high-sensitive reporter cells resemble patient's viremia. <i>Journal of Microbiology, Immunology and Infection</i> , 2018, 51, 446-455.	3.1	6
27	IDDF2018-ABS-0106...Tenofovir alafenamide (taf) compared with tenofovir disoproxil fumarate (tdf) in patients with chronic hbv: week 96 efficacy and safety results in chinese patients enrolled in 2 global phase 3 studies. , 2018, , .		0
28	Fucosyl-Agalactosyl IgG1 Induces Cholangiocarcinoma Metastasis and Early Recurrence by Activating Tumor-Associated Macrophage. <i>Cancers</i> , 2018, 10, 460.	3.7	6
29	Applications of next-generation sequencing analysis for the detection of hepatocellular carcinoma-associated hepatitis B virus mutations. <i>Journal of Biomedical Science</i> , 2018, 25, 51.	7.0	24
30	Progesterone receptor membrane component 1 as a potential prognostic biomarker for hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2018, 24, 1152-1166.	3.3	24
31	Clinical utility of hepatitis B surface antigen kinetics in treatment-naïve chronic hepatitis B patients during long-term entecavir therapy. <i>World Journal of Gastroenterology</i> , 2018, 24, 725-736.	3.3	8
32	Decrease in regulatory T-cell function in chronic hepatitis C patients receiving pegylated-interferon plus ribavirin. <i>International Journal of Infectious Diseases</i> , 2017, 58, 8-17.	3.3	3
33	Favorable Response to Long-term Nucleos(t)ide Analogue Therapy in HBeAg-positive Patients with High Serum Fucosyl-Agalactosyl IgG. <i>Scientific Reports</i> , 2017, 7, 1957.	3.3	3
34	Daclatasvir/asunaprevir/beclabuvir, all-oral, fixed-dose combination for patients with chronic hepatitis C virus genotype 1. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1998-2005.	2.8	15
35	Hepatocellular carcinoma-associated single-nucleotide variants and deletions identified by the use of genome-wide high-throughput analysis of hepatitis B virus. <i>Journal of Pathology</i> , 2017, 243, 176-192.	4.5	29
36	Detecting exact breakpoints of deletions with diversity in hepatitis B viral genomic DNA from next-generation sequencing data. <i>Methods</i> , 2017, 129, 24-32.	3.8	4

#	ARTICLE	IF	CITATIONS
37	Lipoprotein lipase liberates free fatty acids to inhibit HCV infection and prevent hepatic lipid accumulation. <i>Cellular Microbiology</i> , 2017, 19, e12673.	2.1	12
38	Peg-Interferon Lambda Treatment Induces Robust Innate and Adaptive Immunity in Chronic Hepatitis B Patients. <i>Frontiers in Immunology</i> , 2017, 8, 621.	4.8	48
39	Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin. <i>Clinical Interventions in Aging</i> , 2016, Volume 11, 1035-1041.	2.9	8
40	Association of sustained virologic response with reduced progression to liver cirrhosis in elderly patients with chronic hepatitis C. <i>Clinical Interventions in Aging</i> , 2016, 11, 327.	2.9	2
41	Ledipasvir/sofosbuvir fixed-dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virus. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1323-1329.	2.8	22
42	Oral daclatasvir plus asunaprevir for chronic hepatitis C virus (HCV) genotype 1b infection: a sub-analysis in Asian patients from the HALLMARK DUAL study. <i>Liver International</i> , 2016, 36, 1433-1441.	3.9	25
43	DeF-GPU: Efficient and effective deletions finding in hepatitis B viral genomic DNA using a GPU architecture. <i>Methods</i> , 2016, 111, 56-63.	3.8	4
44	A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infection. <i>Liver International</i> , 2016, 36, 1101-1107.	3.9	28
45	Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B). <i>Journal of Hepatology</i> , 2016, 64, 1011-1019.	3.7	84
46	Aligning to the sample-specific reference sequence to optimize the accuracy of next-generation sequencing analysis for hepatitis B virus. <i>Hepatology International</i> , 2016, 10, 147-157.	4.2	12
47	Prediction of early hepatocellular carcinoma recurrence using germinal center kinase-like kinase. <i>Oncotarget</i> , 2016, 7, 49765-49776.	1.8	9
48	Resistance of ground glass hepatocytes to oral antivirals in chronic hepatitis B patients and implication for the development of hepatocellular carcinoma. <i>Oncotarget</i> , 2016, 7, 27724-27734.	1.8	26
49	Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine. <i>World Journal of Gastroenterology</i> , 2015, 21, 4644-4651.	3.3	25
50	Comprehensive DNA methylation analysis of hepatitis B virus genome in infected liver tissues. <i>Scientific Reports</i> , 2015, 5, 10478.	3.3	41
51	Changing hepatitis D virus epidemiology in a hepatitis B virus endemic area with a national vaccination program. <i>Hepatology</i> , 2015, 61, 1870-1879.	7.3	63
52	Aberrant Serum Immunoglobulin G Glycosylation in Chronic Hepatitis B Is Associated With Histological Liver Damage and Reversible by Antiviral Therapy. <i>Journal of Infectious Diseases</i> , 2015, 211, 115-124.	4.0	38
53	HBsAg expression of liver correlates with histological activities and viral replication in chronic hepatitis B. <i>Annals of Hepatology</i> , 2014, 13, 771-780.	1.5	5
54	Association of serum IgG N-glycome and transforming growth factor- $\beta$ 1 with hepatitis B virus e antigen seroconversion during entecavir therapy. <i>Antiviral Research</i> , 2014, 111, 121-128.	4.1	11

#	ARTICLE	IF	CITATIONS
55	All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. <i>Lancet</i> , The, 2014, 384, 1597-1605.	13.7	316
56	Effects of Tenofovir Disoproxil Fumarate in Hepatitis B e Antigen-Positive Patients With Normal Levels of Alanine Aminotransferase and High Levels of Hepatitis B Virus DNA. <i>Gastroenterology</i> , 2014, 146, 1240-1248.	1.3	151
57	Apolipoprotein J, a glucose-upregulated molecular chaperone, stabilizes core and NS5A to promote infectious hepatitis C virus virion production. <i>Journal of Hepatology</i> , 2014, 61, 984-993.	3.7	46
58	Efficacy of Entecavir in Chronic Hepatitis B Patients with Persistently Normal Alanine Aminotransferase: Randomized, Double-Blind, Placebo-Controlled Study. <i>Antiviral Therapy</i> , 2014, 19, 755-764.	1.0	13
59	Peginterferon Alfa-2a Is Associated with Elevations in Alanine Aminotransferase at the End of Treatment in Chronic Hepatitis C Patients with Sustained Virologic Response. <i>PLoS ONE</i> , 2014, 9, e100207.	2.5	4
60	Clinical significance of serum HBsAg levels and association with liver histology in HBeAg positive chronic hepatitis B. <i>Journal of Clinical Virology</i> , 2013, 57, 323-330.	3.1	13
61	Improvement in liver histology among Asian patients with chronic hepatitis B after long-term treatment with entecavir. <i>Liver International</i> , 2013, 33, 650-651.	3.9	6
62	Quantitative hepatitis B surface antigen analysis in hepatitis B e antigen-positive, nucleoside-naive patients treated with entecavir. <i>Antiviral Therapy</i> , 2013, 18, 691-698.	1.0	18
63	Long-term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901. <i>Expert Opinion on Drug Safety</i> , 2012, 11, 361-368.	2.4	53
64	High Rates of Viral Suppression After Long-term Entecavir Treatment of Asian Patients With Hepatitis B e Antigen-Positive Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 1047-1050.e1.	4.4	14
65	Analysis of Precore/Core Covariances Associated with Viral Kinetics and Genotypes in Hepatitis B e Antigen-Positive Chronic Hepatitis B Patients. <i>PLoS ONE</i> , 2012, 7, e32553.	2.5	3
66	Discovering Clinical Biomarkers of Chronic Hepatitis B by Mining Mutation Hotspots. , 2011, , .		4
67	A Locked Nucleic Acid Clamp-Mediated PCR Assay for Detection of a p53 Codon 249 Hotspot Mutation in Urine. <i>Journal of Molecular Diagnostics</i> , 2011, 13, 474-484.	2.8	45
68	Association of intrahepatic cccDNA reduction with the improvement of liver histology in chronic hepatitis B patients receiving oral antiviral agents. <i>Journal of Medical Virology</i> , 2011, 83, 602-607.	5.0	37
69	Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. <i>Hepatology</i> , 2011, 53, 62-72.	7.3	274
70	Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. <i>Hepatology</i> , 2010, 51, 422-430.	7.3	515
71	Efficacy of entecavir in chronic hepatitis B patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage. <i>Hepatology</i> , 2010, 51, 1185-1189.	7.3	45
72	Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. <i>Hepatology</i> , 2010, 52, 886-893.	7.3	840

#	ARTICLE	IF	CITATIONS
73	On-treatment monitoring of HBV DNA levels: predicting response and resistance to oral antiviral therapy at week 24 versus week 48. <i>Hepatology International</i> , 2009, 3, 16-23.	4.2	7
74	Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: The case for continuous antiviral therapy. <i>Journal of Hepatology</i> , 2009, 50, 289-295.	3.7	96
75	Current approaches for treating chronic hepatitis B: when to start, what to start with, and when to stop. <i>Hepatology International</i> , 2008, 2, 19-27.	4.2	8
76	Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. <i>Hepatology</i> , 2008, 48, 750-758.	7.3	300
77	Genotyping of Hepatitis B Virus " Genotypes A to G by Multiplex Polymerase Chain Reaction. <i>Intervirology</i> , 2008, 51, 247-252.	2.8	18
78	Entecavir: a potent antiviral with minimal long-term resistance in nucleoside-naïve chronic hepatitis B patients. <i>Expert Review of Anti-Infective Therapy</i> , 2008, 6, 569-579.	4.4	18
79	Sustained Hepatitis B e Antigen Seroconversion in Patients with Chronic Hepatitis B after Adefovir Dipivoxil Treatment: Analysis of Precore and Basal Core Promoter Mutants. <i>Clinical Infectious Diseases</i> , 2008, 47, 1305-1311.	5.8	15
80	Five subgenotypes of hepatitis B virus genotype B with distinct geographic and virological characteristics. <i>Virus Research</i> , 2007, 129, 212-223.	2.2	24
81	Entecavir Therapy for up to 96 Weeks in Patients With HBeAg-Positive Chronic Hepatitis B. <i>Gastroenterology</i> , 2007, 133, 1437-1444.	1.3	324
82	Characterization of viral kinetics in patients with hepatitis B e antigen-positive chronic hepatitis B. <i>Journal of Medical Virology</i> , 2007, 79, 663-669.	5.0	6
83	Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years. <i>Gastroenterology</i> , 2006, 131, 1743-1751.	1.3	832
84	Hepatitis B Virus with Primary Resistance to Adefovir. <i>New England Journal of Medicine</i> , 2006, 355, 322-323.	27.0	42
85	Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis B. <i>New England Journal of Medicine</i> , 2006, 354, 1011-1020.	27.0	1,118
86	Simultaneous Quantification and Genotyping of Hepatitis B Virus for Genotypes A to G by Real-Time PCR and Two-Step Melting Curve Analysis. <i>Journal of Clinical Microbiology</i> , 2006, 44, 4491-4497.	3.9	31
87	A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis B. <i>New England Journal of Medicine</i> , 2006, 354, 1001-1010.	27.0	1,345
88	A Dose-Ranging Study of the Efficacy and Tolerability of Entecavir in Lamivudine-Refractory Chronic Hepatitis B Patients. <i>Gastroenterology</i> , 2005, 129, 1198-1209.	1.3	247
89	Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2004, 19, 1276-1282.	2.8	227
90	Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen-Positive Chronic Hepatitis B. <i>New England Journal of Medicine</i> , 2003, 348, 808-816.	27.0	1,297

#	ARTICLE	IF	CITATIONS
91	Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen-“Negative Chronic Hepatitis B. New England Journal of Medicine, 2003, 348, 800-807.	27.0	971
92	Prevalence and significance of hepatitis B virus (HBV) pre-S mutants in serum and liver at different replicative stages of chronic HBV infection. Hepatology, 2001, 33, 277-286.	7.3	183
93	Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy. Hepatology, 2001, 33, 1527-1532.	7.3	565
94	Limitations and improvements of the quantiplex branched-DNA assay in Hepatitis B virus-infected patients receiving lamivudine. Journal of Virological Methods, 2001, 96, 203-210.	2.1	2
95	Existence of Hepatitis C Virus in Culex quinquefasciatus after Ingestion of Infected Blood: Experimental Approach to Evaluating Transmission by Mosquitoes. Journal of Clinical Microbiology, 2001, 39, 3353-3355.	3.9	13
96	Identification of a pre-“S2 mutant in hepatocytes expressing a novel marginal pattern of surface antigen in advanced diseases of chronic hepatitis B virus infection. Journal of Gastroenterology and Hepatology (Australia), 2000, 15, 519-528.	2.8	54
97	GB virus-C/hepatitis G virus infection in a hepatitis C virus endemic village: prevalence in residents with low educational attainment and frequent recovery in females. Liver International, 2000, 20, 222-227.	3.9	2
98	Plastic Microchip Electrophoresis for Analysis of PCR Products of Hepatitis C Virus. Clinical Chemistry, 1999, 45, 1938-1943.	3.2	70
99	The value of serum tissue polypeptide specific antigen in the diagnosis of hepatocellular carcinoma. , 1999, 85, 1039-1043.		18
100	A One-Year Trial of Lamivudine for Chronic Hepatitis B. New England Journal of Medicine, 1998, 339, 61-68.	27.0	1,773
101	Incidence of post-“transfusion hepatitis in Taiwan before and after introduction of anti-“HCV testing. Liver, 1996, 16, 201-206.	0.1	9
102	Intrafamilial transmission of hepatitis C virus: The important role of inapparent transmission. Journal of Medical Virology, 1994, 42, 91-96.	5.0	69
103	Hepatitis B and hepatitis C among institutionalized psychiatric patients in Taiwan. Journal of Medical Virology, 1993, 40, 170-173.	5.0	30
104	Detection of hepatitis C virus RNA in peripheral blood mononuclear cells and in saliva. Journal of Medical Virology, 1993, 41, 55-60.	5.0	71
105	Cholelithiasis treated by ethylenediaminetetraacetic acid infusion through an endoscopic nasobiliary catheter. Journal of Gastroenterology and Hepatology (Australia), 1992, 7, 335-338.	2.8	5
106	Detection of HCV RNA in saliva, urine, seminal fluid, and ascites. Journal of Medical Virology, 1992, 37, 197-202.	5.0	184